glp-1 receptor agonists should be avoided in patients with Impact of GLP- 1 Agonist Therapy High Risk for Sarcopenia | Current Nutrition Reports GLP-1 Receptor Agonists as Treatments
Description
However, it is postulated from preclinical data that incorporating GCG receptor agonism may reduce food intake and increase resting energy expenditure, potentially enhancing efficacy
NCT02970942 results [2] Among patients treated with semaglutide, those in the 0.4 mg group experienced an average weight loss of 13%, compared to 1% in the placebo group
A.CoskunT.SammsR
doi: 10.1016/j.tem.2016.10.001 [DOI] [PubMed] [Google Scholar] 25
Exenatide, a peptide of 39 amino acids, has a much slower metabolism than endogenous GLP-1 (half-life of 3-4 h) (119, 120)
